(Reuters) – The New York Stock Exchange opened in dispersed order on Tuesday while trade negotiations between the United States and China continue for a second day in London.
In the first exchanges, the Dow Jones index loses 21.76 points, or 0.05%, at 42,740.00 points and the Standard & Poor’s 500, wider, increased from 0.14% to 6.014.24 points.
The Nasdaq Composite takes 0.16%, or 30.35 points, at 19,621.58 points.
High representatives of the United States and China gathered in London for commercial negotiations are continuing their discussions for a second consecutive day in the British capital, in an attempt to defuse a commercial conflict with considerable issues.
The American secretary of trade, Howard Lunick, said that the discussions lasted all day on Monday, adding that he expected that they also last all day on Tuesday. “They (discussions) go well and we spend a lot of time together,” he said.
Alongside Howard Lunick, negotiations are led by the American secretary to the Treasury, Scott Bessent, and the American representative on trade, Jamieson Greer, while the Chinese contingent is led by He Lifeng, the Deputy Prime Minister.
Any advance in negotiations should relieve markets, given the fact that Trump’s often contradictory customs duties and fluctuations in Sino-American relations have weakened the two economies, disrupted supply chains and threaten global growth.
At the values, Insmed advances by 26.13% after his experimental drug against high blood pressure achieved the main secondary objectives of an intermediate phase study.
JM SMUCKER lost 6.57% after having announced on Tuesday forecasts for annual profits below estimates, the successive price increases having weighed at the request of his snacks for dogs and his sweet pastries.
Recurrence Pharmaceuticals is advancing 7.08% after announcing on Tuesday the abolition of around 20% of its workforce and its intention to focus on the development of rare disease drugs and cancers in order to reduce the consumption of liquidity in a context of prolonged slowdown in the biotechnological industry.
(Written by Mara Vîlcu, edited by Blandine Hénault)
Copyright © 2025 Thomson Reuters
I have over 8 years of experience working in the news industry. I have worked as a reporter, editor, and now managing editor at 247 News Agency. I am responsible for the day-to-day operations of the news website and overseeing all of the content that is published. I also write a column for the website, covering mostly market news.
